Wegovy

targets

all catalysts(0)

nothing on the calendar yet

News(10)

• STAT+: Pharmalittle: We’re reading about an FDA commish nominee, mRNA cancer vaccine results, and more
  President Trump is expected to nominate Heidi Overton, White House deputy director of domestic policy, to serve as the next FDA commissioner
  stat · 1d ago
• Enveda’s exercise-simulating obesity tablet clears early clinical test
  Touting an “exceptional” gastrointestinal safety profile for its oral obesity drug candidate in a study of healthy volunteers, Enveda plans to test the asset in people stopping GLP-1 treatment.
  biospace · 1d ago
• Novo takes first round of oral obesity duel. Can it stay ahead of Lilly?
  Despite coming away with an early victory over Eli Lilly in the oral obesity face-off, analysts don’t expect Novo Nordisk’s lead to last for very long.
  biospace · 1d ago
• Amylyx eyes FDA filing for GLP-1 blocker after late-stage win in post-bariatric hypoglycemia
  With a Phase 3 trial showing a reduction of serious and severe hypoglycemic episodes in patients who have undergone weight loss surgery, Amylyx Pharmaceuticals plans to file for approval this year.…
  biospace · 2d ago
• Amylyx readies approval push after GLP-1 inhibitor halves blood sugar crashes in ph. 3 win
  Amylyx Pharmaceuticals’ $35 million bet on the GLP-1 receptor antagonist avexitide appears to have paid off, with the molecule cutting the number of dangerous blood sugar crashes by more than half…
  fiercebiotech · 2d ago
• Skye and Redx form new entity with $125M to advance fibrosis assets
  Skye Bioscience has entered into an agreement to combine with privately held fibrotic disease biotech Redx Pharma in a deal that will net $125 million in financing for the new public company, calle…
  fiercebiotech · 6d ago
• STAT+: Pharmalittle: We’re reading about California insulin sales, a Moderna patent battle, and more
  Seven months after the launch of its own low-cost insulin brand, California has distributed more than 120,000 five-pen packs of insulin glargine priced at $55 each
  stat · 7d ago
• Replimune finally wins approval, Q2 earnings wrap up, psychedelics stay in spotlight
  After two rejections, Replimune has made it across the regulatory finish line with its advanced melanoma therapy. Meanwhile, the last of the major pharmas, including Eli Lilly and Novo Nordisk, rep…
  biospace · 8d ago
• Scholar Rock rejigs approval filing after FDA flags violations at Novo plant
  Despite earlier claims of improvement at the fill-finish plant, the FDA has classified the facility as Official Action Indicated based on inspection findings.
  biospace · 9d ago
• After tasting IPO success, Hemab’s CEO seeks ‘flavor of a multi-product coagulation company’
  With the post-IPO quiet period having come to an end, CEO Benny Sørensen, M.D., Ph.D., was free to sit down with Fierce to map out Hemab’s future.
  fiercebiotech · 9d ago